Year: 2022

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that  the Food and Drug Administration (“FDA”) has set a date of 7th June 2023 for a Type-C meeting to provide guidance on the Phase 2/3 adaptive study of Lupuzor™ (“P140”) in patients with systemic lupus erythematosus (“SLE/Lupus”). This follows on…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further positive progress in its late-stage P140 clinical program in patients with chronic idiopathic demyelinating polyneuropathy (“CIDP”). Key highlights: ImmuPharma has received confirmation from the Food and Drug Administration (“FDA”) for a pre- Investigational New Drug meeting date of 16 May…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to update the market on the next positive step in its Lupuzor™ (P140) program in patients with systemic lupus erythematosus (“SLE/Lupus”). This follows on from the recent announcement on 6 February 2023. Key highlights Avion Pharmaceuticals (“Avion”) and ImmuPharma agreed in February on…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that it has signed an initial collaboration agreement on the Company’s peptide technology, with Orano SA (“Orano”), a leading international corporation and a key player in the nuclear energy sector.  Key points: Orano has paid a small undisclosed amount to ImmuPharma…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market on its Lupuzor™ programme in patients with systemic lupus erythematosus (“SLE”) Key highlights: In conjunction with its partner Avion Pharmaceuticals (“Avion”), ImmuPharma confirms that a Phase 2/3 adaptive trial will be the best design for the next clinical study…

Notification of major holdings Click here

NOTIFICATION OF MAJOR HOLDINGS Click here

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows. The Remuneration Committee (comprising the Non Executive Directors) has determined to award  Share Options to the Executive Directors with exercise prices and conditions which reflect the underlying objective of restoring and enhancing shareholder value as follows: Tim…

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market. Review of 2022 and Outlook for 2023 As we approach the end of 2022 the Company can confirm that it continues to work proactively, together with our partner Avion Pharmaceuticals (“Avion) and external advisors, on the preparations around the…